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Introduction {#sec001}
============

Sepsis is as a life-threatening organ dysfunction caused by a dysregulated host response to infection with major impact worldwide \[[@pone.0238039.ref001]\]. Septic shock, the deadliest form of sepsis, is characterized by low systemic blood pressure despite fluid resuscitation, organ dysfunction and high mortality, especially when accompanied by myocardial depression \[[@pone.0238039.ref002],[@pone.0238039.ref003]\]. The precise mechanisms of organ dysfunction in sepsis still remain elusive, especially the induced-cardiac dysfunction \[[@pone.0238039.ref004],[@pone.0238039.ref005]\].

Dipeptidyl peptidase 3 (DPP3) is a ubiquitously expressed intracellular enzyme that is involved in the cleavage of small peptides \[[@pone.0238039.ref006]\]. Exact roles of DPP3 in the heart and especially in cardiac cells are not completely understood. We recently showed that circulating DPP3 (cDPP3) was elevated in cardiogenic shock patients and that high levels of cDPP3 were associated with altered hemodynamic and poor outcomes \[[@pone.0238039.ref007]\]. Experimental studies showed that bolus administration of natively purified human DPP3 provoked a rapid and marked deterioration of heart contractile function in healthy mice \[[@pone.0238039.ref007]\]. Furthermore, inhibition of cDPP3 by its specific antibody, Procizumab (PCZ), promptly restored cardiac contractility and decreased myocardial oxidative stress in a mouse model of acute cardiac stress, in which cDPP3 is increased \[[@pone.0238039.ref007]\].

In a preliminary study of a cohort of septic patients, those patients with septic shock showed higher levels of cDPP3 compared to patients with severe sepsis \[[@pone.0238039.ref008]\]. We hypothesised that cDPP3 could have a role in the pathophysiology of cardiac dysfunction during septic shock. We, therefore, evaluated the effect of DPP3 inhibition by PCZ in a rat model of cardiac dysfunction induced by septic shock.

Material and methods {#sec002}
====================

Sepsis model {#sec003}
------------

Three-month-old male Wistar rats weighing 350--450 g (Janvier, St Berthevin, France) were used. All experiments were conducted in accordance with the National and European Institutes of Health Guidelines for the use of laboratory rats and were approved by the research ethics committee of Paris University (protocol number S140 \#9385) and complied to ARRIVE guidelines and all efforts were made to minimize suffering. Septic shock and hemodynamic monitoring were done as previously described \[[@pone.0238039.ref009],[@pone.0238039.ref010]\]. All rats were anaesthetized using an intraperitoneal injection of ketamine hydrochloride (90 mg/kg) and xylazine (9 mg/kg). Polymicrobial sepsis was provoked by cecal ligation and puncture (CLP) as previously described \[[@pone.0238039.ref010]\]. Briefly, a ventral midline incision (1 cm) was made to allow exteriorization of the caecum. The caecum was then ligated just below the ileocecal valve and punctured once with an 18-gauge needle. The abdominal cavity was closed in two layers, and rats were given fluid resuscitation (3 mL/100 g of body weight) of saline, injected subcutaneously). A sham operation was carried out by isolating the caecum with neither ligation nor puncture (sham + PBS group). Intraperitoneal injection of 75 μg/kg of buprenorphine was used for analgesic purposes in the preoperative period. Pain was evaluated by using visual analogue scale score sheet after CLP surgery, and analgesia was adapted by using buprenorphine if needed. 16 hours later, after general anaesthesia with ketamine hydrochloride (90 mg/kg) and xylazine (9mg/kg), rats were placed in the supine position and intubated with a 16 G catheter and ventilated using a rodent ventilator with the respiratory rate set at 53.5 x weight^-0.26^ and the tidal volume set at 6.2 x weight^1.01^ \[[@pone.0238039.ref009]\]. Rectal temperature was maintained throughout the protocol at 37--37.5°C by a heating mat. Catheters were inserted into the left jugular vein to administer treatment or placebo and into the right carotid artery for invasive blood pressure monitoring.

Based on the SEPSIS-3 consensus definition of septic shock \[[@pone.0238039.ref001]\], we only included rats with mean blood pressure (MBP) below 65 mmHg. To ensure cardiac dysfunction, we included only rats with a left ventricular shortening fraction (LVSF) below 45%. We plan to have 5 animals alive at the end of the 120 min hemodynamic study. To do so, we initially blinded five animals in each group (CLP + PBS and CLP + PCZ). Given the high mortality before the end of the 120-minute follow-up in the CLP + PBS group, we had to include additional animals to achieve 5 animals surviving at 120 minutes in this group. After a bolus injection of 1.5 mL PBS or PCZ (concentration of 1 mg/ml) through the jugular vein in 5 min, which is equivalent as a fluid resuscitation, PBS (2 mL) and PCZ were continuously infused with an electric syringe (2 mL at the concentration of 0.42 mg/mL) during the 120 minutes of follow-up. The experimental protocol is summarized in [Fig 1A](#pone.0238039.g001){ref-type="fig"}.

![Design and flow chart of the study.\
(A) Schematic representation of the preclinical experiment in rats, including treatments and hemodynamic assessment (BP: blood pressure, CLP: cecal ligation and puncture, PBS: phosphate buffered saline, PCZ: Procizumab, TTE: transthoracic echocardiography). (B) Flowchart of rat's randomization.](pone.0238039.g001){#pone.0238039.g001}

Hemodynamics and cardiac function monitoring {#sec004}
--------------------------------------------

Monitoring of hemodynamics and cardiac function was performed as previously described \[[@pone.0238039.ref009],[@pone.0238039.ref011]\]. Echocardiography parameters were measured by transthoracic echocardiography (TTE) using Vivid 7 system (General Electrics, USA) equipped with a 14-MHz linear transducer for rats, before randomization (16 hours after CLP or sham procedure) and every 30 min during the 120 minutes of the protocol ([Fig 1A](#pone.0238039.g001){ref-type="fig"}). All acquisitions were recorded digitally and stored for subsequent off-line analysis \[[@pone.0238039.ref012]\]. Invasive blood pressure measurements, by using arterial catheter in carotid artery and recorded by Biopac^®^ system and AcqKnowledge^®^ 5.0 software (California, USA) for data acquisition, were done before randomization and every 30 minutes after the beginning of therapy (PBS or PCZ injection) during the 120 minutes of the protocol.

Inhibition of DPP3 activity by PCZ {#sec005}
----------------------------------

Generation, screening and development of humanized anti-DPP3 antibody PCZ was previously described \[[@pone.0238039.ref007]\]. In addition, the humanized DPP3-inhibiting antibody Procizumab binds to a conserved, surface exposed loop in proximity to the active site. Crystal structures of human DPP3 in apo and substrate-bound forms show that the enzyme undergoes a large conformational change between the open (apo) state and the closed (substrate-bound state). Since the epitope targeted by Procizumab remains exposed in the surface in the open and closed states, it is expected that the antibody binds the enzyme regardless of its conformation and sterically blocks the transition between DPP3 catalytic states, therefore, inhibiting enzyme activity.

Anatomical examination and tissue preparation {#sec006}
---------------------------------------------

At the end of the protocol, the rats were sacrificed by lethal anaesthesia with an injection of 40mg/kg of pentobarbital solution (CEVA, Libourne, France). The heart was transversally divided into two parts: the base part was embedded into Tissue-Tek optimal cutting temperature (OCT) compound (VWR Chemicals, Jeuven, Belgium) and frozen into liquid nitrogen pre-cooled isopentane; the apex was snap-frozen in liquid nitrogen. All samples were stored at −80°C for further analyses. Heparin blood was collected from the left carotid artery at the end of the experiment, centrifuged at 3500 rpm for 15 min at 4°C, and plasma was stored at -80°C.

Plasma DPP3 activity {#sec007}
--------------------

Plasma DPP3 activity was measured using the soluble activity assay (SAA) with a fluorogenic substrate (15). Briefly, 10 μl of rat heparin-plasma were incubated with 90 μl of a substrate reagent solution (50 mM Tris/HCl, pH 7.8 (25°C), 0.125% Triton X-100, 100 μM Arg2-β-napthylamide (Arg2-βNA, Bachem AG) for 1 h at 37°C in black 96-well microtiter plates. Fluorescence of the cleaved product βNA was detected at 420 nm using the Twinkle LB 970 fluorometer (Berthold Technologies GmbH).

Gene expression analyses {#sec008}
------------------------

Total RNA were isolated from tissues using the RNeasy Mini Kit^®^ (Qiagen, Courtaboeuf, France) according to the manufacturer's instructions and reverse transcribed using QuantiTect^®^ Reverse Transcription (Qiagen, Courtaboeuf, France). Subsequently, real-time quantitative polymerase chain reaction was performed on a LightCycler96 (Roche Diagnostics, Meylan, France) using the FastStart Essential DNA Green Master^®^ (Roche Diagnostics, Meylan, France). Transcripts levels for genes of interest were normalized to that of Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and expressed as the relative change compared to the control samples. The sequences of the primers used are reported in [S1 Table](#pone.0238039.s003){ref-type="supplementary-material"}.

Dihydroethidium staining {#sec009}
------------------------

Dihydroethidium staining (DHE, Sigma-Aldrich) was performed on 7 μm myocardial cross-cryosection as previously described \[[@pone.0238039.ref007],[@pone.0238039.ref009]\].

Statistical analysis {#sec010}
--------------------

Data are expressed as mean ± SD. Normality was assessed using the Shapiro--Wilk test. For two-group comparisons, Wilcoxon signed-rank test or Wilcoxon rank-sum test were used as appropriate. Comparison between more than two groups was performed by one-way ANOVA, Kruskal--Wallis test or repeated-measures ANOVA followed by Dunn's multiple comparison test, as appropriate. A Kaplan-Meier curve and log-rank survival were done with a 95% confidence interval to evaluate survival. A p-value \<0.05 was considered statistically significant. Statistical analysis was realized using R software (R Core Team, 2014) and figures were produced using ggplot2 (Wickham 2009).

Results {#sec011}
=======

PCZ decreased plasmatic DPP3 activity and myocardial DPP3 transcription in septic rats {#sec012}
--------------------------------------------------------------------------------------

Sixteen hours after the CLP or sham procedure, clinical signs of sepsis (reduced motor activity, lethargy, shivering, piloerection and hunched posture) were only present in CLP and not in sham + PBS rats. Furthermore, post-mortem examination of the abdominal cavity of all CLP rats showed varying degrees of peritonitis with a grey-black dilated caecum and purulent and malodorous peritoneal fluid. Overall, thirty-six rats were enrolled in the study: 11 in the CLP + PBS group, 6 in the CLP + PCZ group, and 12 in the sham + PBS group ([Fig 1B](#pone.0238039.g001){ref-type="fig"}). Baseline characteristics of the sham and CLP rats after randomisation are summarized in [Table 1](#pone.0238039.t001){ref-type="table"}.

10.1371/journal.pone.0238039.t001

###### Hemodynamics and cardiac parameters in sham and CLP rats before randomisation (i.e. before PBS or PCZ injection).

![](pone.0238039.t001){#pone.0238039.t001g}

                         Sham               CLP before randomization   p
  ---------------------- ------------------ -------------------------- -------------
  **LVSF (mean ± SD)**   **54 ± 7%**        **39 ± 4%**                **\<0.001**
  **SBP (mean ± SD)**    **99 ± 11 mmHg**   **79 ± 10 mmHg**           **\<0.001**
  **DBP (mean ± SD)**    **70 ± 12 mmHg**   **46 ± 10 mmHg**           **\<0.001**
  **MBP (mean ± SD)**    **79 ± 11 mmHg**   **57 ± 8 mmHg**            **\<0.001**
  **HR (mean ± SD)**     321 ± 77 bpm       341 ± 62 bpm               0.428
  **CO (mean ± SD)**     113 ± 33 mL/min    99 ± 26 mL/min             0.231
  **SV (mean ± SD)**     0.4 ± 0.1 mL       0.3 ± 0.1 mL               0.064

Values are expressed as mean ± SD. Comparisons were done by using the Wilcoxon rank-sum test. (CO: cardiac output, DBP: diastolic blood pressure, HR: heart rate, LVSF: left ventricular shortening fraction, MBP: mean blood pressure, SBP: systolic blood pressure, SV: stroke volume).

Interestingly, we found that the CLP + PBS rats had a higher cDPP3 plasma activity than the sham + PBS rats at 120 min (735 ± 255 UI/L vs 94 ± 41 UI/L, p = 0.0063 respectively) ([Fig 2A](#pone.0238039.g002){ref-type="fig"}). Similarly, *DPP3* transcripts were up-regulated in the heart of the CLP + PBS rats compared to the sham + PBS group (1.17 ± 0.40 AU in CLP + PBS compared to 0.52 ± 0.10 in the sham + PBS group, p\<0.001) ([Fig 2B](#pone.0238039.g002){ref-type="fig"}). Plasma cDPP3 activity was lower at 120 min in the PCZ group when compared to the PBS group (138 ± 139 U/L vs 735 ± 722 U/L, p = 0.048) ([Fig 2A](#pone.0238039.g002){ref-type="fig"}), without modifying the myocardial transcription of *DPP3* (1.59 ± 0.35 vs 1.17.± 0.13 in CLP + PBS group, p = 0.27) ([Fig 2B](#pone.0238039.g002){ref-type="fig"}).

![PCZ injection decreased DPP3 plasmatic activity and improved hemodynamics and cardiac function during sepsis.\
(A) Plasmatic DPP3 activity in sham + PBS, CLP + PBS and CLP + PCZ groups. Comparisons were made using Wilcoxon rank-sum test. (B) Myocardial qPCR of DPP3 of sham + PBS, CLP + PBS and CLP + PCZ rats. Comparisons were made by Wilcoxon rank-sum test. (C) Schematic representation of the evolution of the left ventricular shortening fraction in time in sham + PBS (blue dashed line), CLP + PBS (grey line) and CLP + PCZ groups (black line) (p\<0.05 using repeated measures ANOVA). Red dashed line corresponds to the moment of bolus injection followed by infusion. (D) Evolution of the cardiac output, (E) stroke volume, (F) heart rate and (G) mean blood pressure before randomization and 120 min after therapy by PBS or PCZ injection in septic rats. Comparisons were realized by using Wilcoxon rank-sum test. (bpm: beats per minutes, CLP: cecal ligature and puncture).](pone.0238039.g002){#pone.0238039.g002}

PCZ promptly restored cardiac systolic dysfunction in septic rats {#sec013}
-----------------------------------------------------------------

PCZ administration rapidly restored LVSF from 39 ± 4% to 51 ± 2% within 30 min of PCZ initiation (p = 0.004). LVSF was higher in CLP + PCZ group when compared to CLP + PBS group (p\<0.001) ([Fig 2C](#pone.0238039.g002){ref-type="fig"}). The LVSF of the PBS rats remained unchanged (p = 0.556; [Fig 2C](#pone.0238039.g002){ref-type="fig"}). At the end of the protocol--i.e. 120 minutes after the initiation of PCZ or PBS---administration of PCZ was associated with a greater CO ([Fig 2D](#pone.0238039.g002){ref-type="fig"}) and SV ([Fig 2E](#pone.0238039.g002){ref-type="fig"}) compared to the rats receiving PBS. In contrast, heart rate (HR) and MBP measured at 120 minutes were similar in all CLP groups ([Fig 2F and 2G](#pone.0238039.g002){ref-type="fig"}). Finally, the survival rate was higher at 120 min in the PCZ group compared to the PBS group (83% versus 63%, p = 0.0026, log-rank test) ([S1 Fig](#pone.0238039.s001){ref-type="supplementary-material"}). Of note, LVSF and other hemodynamic parameters remained stable throughout the duration of the experiment in the sham + PBS group ([S2 Fig](#pone.0238039.s002){ref-type="supplementary-material"}).

At the cardiac level, PCZ administration rapidly reduced oxidative stress in the heart, measured by DHE staining, compared to PBS administration (13.3 ± 8.2 vs 6.2 ± 2.5 UI, p = 0.0047, 120 min after PBS or PCZ injection, respectively; [Fig 3A and 3B](#pone.0238039.g003){ref-type="fig"}). However, the PCZ effect was not accompanied by any change in the myocardial *HO-1* and *NQO1* expression, two oxidative stress-induced genes (7.90 ± 4.38 AU CLP + PCZ vs 5.42 ± 2.03 AU CLP + PBS p = 0.33 and 5.21 ± 2.33 AU CLP + PCZ vs 4.49 ± 1.91 CLP+PBS, p = 0.61) ([Fig 3C and 3D](#pone.0238039.g003){ref-type="fig"}).

![PCZ injection improved myocardial oxidative stress.\
Representative images (A) and quantification (B) of DHE staining from myocardial sections of sham + PBS, CLP + PBS and CLP + PCZ rat groups. Myocardial mRNA expression of *HO-1* and *NQO-1* in sham + PBS, CLP + PBS and CLP + PCZ groups. Comparisons were made by Wilcoxon rank-sum test. (DHE: dihydroethidium, *HO-1*: heme oxygenase 1, *NQO-1*: NAD(P)H dehydrogenase (quinone 1)).](pone.0238039.g003){#pone.0238039.g003}

Discussion {#sec014}
==========

Our study demonstrates that inhibition of cDPP3 by PCZ restored cardiac contractility in septic rats. These data indicate that cDPP3 plays an important part in sepsis-induced myocardial depression and suggest PCZ as a promising therapeutic option in this context. [Fig 4](#pone.0238039.g004){ref-type="fig"} resumes the main findings of our work.

![cDPP3 is implicated in septic myocardial depression.\
Its inhibition by a specific antibody, Procizumab, could be a tool to restore impaired cardiac function. Fig was built using <https://smart.servier.com>.](pone.0238039.g004){#pone.0238039.g004}

The pathophysiology of sepsis-induced myocardial depression is still not fully understood. Parrillo et al. have described for the first time a "myocardial depressant factor" \[[@pone.0238039.ref013]\]. Since this hypothesis was drawn, several factors (including cytokines) were described to be associated with myocardial depression during sepsis or other acute conditions \[[@pone.0238039.ref014]--[@pone.0238039.ref019]\]. Other authors hypothesized that the down-regulation or uncoupling of adrenergic receptors induced by sepsis can explain the absence of response to endogenous and exogenous catecholamines, leading to septic shock \[[@pone.0238039.ref020]\]. Furthermore, an increased oxidative stress level may be implicated in triggering myocardial dysfunction during sepsis \[[@pone.0238039.ref021]--[@pone.0238039.ref023]\]. Finally, alteration of the angiotensin II pathway is another potential, but poorly studied, mechanism implicated in septic cardiomyopathy. The RAAS pathway is clearly modified during sepsis \[[@pone.0238039.ref020]\] with altered angiotensin II levels and reduced angiotensin II sensitivity, via the reduction or the uncoupling of angiotensin II receptors, and the consequent deterioration of its positive inotropic effects \[[@pone.0238039.ref020],[@pone.0238039.ref024]--[@pone.0238039.ref027]\]. In the present study, by using a sepsis-induced model in rat, we demonstrated that blocking cDPP3 with PCZ resulted in prompt and marked cardiac contractile benefits. The present data reinforce cDPP3 as a potential myocardial depressant factor together with previous benefits of PCZ in cardiogenic shock \[[@pone.0238039.ref007]\]. Furthermore, the elevation of plasma cDPP3 could reduce angiotensin II levels by cleavage into angiotensin IV \[[@pone.0238039.ref006],[@pone.0238039.ref028]\], as we previously observed in mouse and human plasma samples spiked with natively purified DPP3 \[[@pone.0238039.ref007]\]. Thus, the restoration of the cardiac function in septic rats by blocking DPP3 could result from the potentiation of angiotensin II that would be normally inactivated. Altogether, these data strongly suggest that cDPP3 could be a sought-after myocardial depressing factor, which would act by decreasing the angiotensin II signalling pathway when increased in septic shock.

Our study has some limitations. First, the duration of the protocol is short as we designed this proof of principle study based on the short life span of the septic rats (18 to 20 hours post-surgery). Second, septic rats have not been fully resuscitated, particularly, we did not treat the rats with antibiotics. However, given the duration of the protocol, the administration of antibiotics is not expected to provide any improvement on the rat status. Along the same line, rats did not receive any exogenous catecholamine as the aim was to evaluate the hemodynamic benefit of cDPP3 inhibition. Nevertheless, further studies are warranted to evaluate the benefit of PCZ in fully resuscitated rats, including probabilistic antibiotherapy and catecholamine administration. Third, the mechanism of action of DPP3 and its inhibition by PCZ in septic cardiomyopathy is currently poorly understood. However, the involvement of blood pressure in the improvement of cardiac function upon PCZ treatment seems to be limited,. Further studies are needed to determine PCZ's mechanism of action in heart function improvement during septic cardiomyopathy. Fourth, DPP3 activity was only measured in plasma since the antibody can only bind and inhibit DPP3 activity in plasma and not inside cells, e.g. cardiac cells. Fifth, we do not assess sex differences responses to PCZ treatment as only male mice were included in this preclinical study. This is a common bias in experimental studies and more studies are needed to fill this gap.

We previously showed that cDPP3 is involved in acute heart failure in mice \[[@pone.0238039.ref007]\]. Our study extends the role of cDPP3 to septic cardiomyopathy. Additionally, inhibition of high levels of cDPP3 by PCZ in septic rats restored cardiac contraction and improved survival, suggesting PCZ as a possible therapeutic option in patients with septic shock, an indication where limited treatment efficacy has been observed \[[@pone.0238039.ref029]\]. The use of PCZ could possibly limit the use of high doses of inotropes during septic shock treatment, which has been associated with deleterious effects \[[@pone.0238039.ref030],[@pone.0238039.ref031]\].

Supporting information {#sec015}
======================

###### Survival curve 120 min after PBS or PCZ injection.

CLP: cecal ligation and puncture, PBS: phosphate buffered saline, PCZ: Procizumab. Log rank test was used.

(TIF)

###### 

Click here for additional data file.

###### Hemodynamics and cardiac parameters remain stable in sham rats.

Schematic representation of the evolution of the left ventricular shortening fraction (A), mean blood pressure (B), cardiac output (C), stoke volume (D) and heart rate (E) 16 hours after sham surgical procedure. Comparisons were made by using repeated measures of ANOVA.

(TIF)

###### 

Click here for additional data file.

###### Primers used for q*PCR*.

(DOCX)

###### 

Click here for additional data file.

###### 

(XLTX)

###### 

Click here for additional data file.
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6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Jean-Louis Vincent

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1: The authors previously showed that dipeptidyl peptidase 3 (DPP3) is a myocardial depressant substance. In this study, they used a model of septic shock induced by peritonitis to show that inhibition of cDPP3 by its specific antibody, procizumab (PCZ), improves the hemodynamic status.

The study is interesting and well performed.

Specific comments

1\. How come the randomization was unbalanced? How was the randomization performed?

Response: According to the ARRIVE guidelines, and to respect the 3R rule, number of tested animals was limited to the minimum required number. Additionally, for statistical reasons, a number of 5 animals per group at 120 min was needed. Because of the high mortality rate observed in the CLP + PBS group, we had to increase the number of animals in this group to reach 5 animals at the 120 min time point.

The randomization of CLP rats in PBS or PCZ groups was blinded in order to obtain a minimum of 5 rats by group. The manuscript has been modified accordingly.

Material and methods section, Page 3, Line 59 "We plan to have 5 animals alive at the end of the 120 min hemodynamic study. To do so, we initially blinded five animals in each group (CLP + PBS and CLP + PCZ). Given the high mortality before the end of the 120-minute follow-up in the CLP + PBS group, we had to include additional animals to achieve 5 animals surviving at 120 minutes in this group.)".

2\. The effects on arterial pressure are hardly considered. It seems that the major effect of PCZ was an increase in arterial pressure, and this could in turn improve myocardial function.

Response: We thank the reviewer for this interesting comment. As shown in Fig 2G, no effect was observed on mean blood pressure 120 min after PCZ administration. Thus, involvement of blood pressure in the improvement of cardiac function seems to be limited. Further studies are needed to determine PCZ's mechanism of action in cardiac improvement during septic cardiomyopathy.

The manuscript was modified accordingly in the limitation section.

Discussion section, Page 10, line 217: "Third, the mechanism of action of DPP3 and its blockage by PCZ in septic cardiomyopathy is currently poorly understood. However, involvement of blood pressure in the improvement of cardiac function upon PCZ treatment seems limited. Further studies are needed to determine PCZ's mechanism of action in cardiac improvement during septic cardiomyopathy"

 

3\. Discussion: the suggestion that DPP3 could be the long-searched myocardial depressing factor is too much. The search for the MDF has been abandoned for a long time: It is now well accepted that there are many myocardial depressant substances.

Response: We thank the reviewer for this comment and we modified the manuscript accordingly.

Discussion section, Page 11, line 224 "We previously showed that cDPP3 is involved in acute heart failure in mice \[7\]. Our study extends the role of cDPP3 to septic cardiomyopathy".

4\. Minor general comment

The text needs language editing: as an example,

-respectively appears before the data

-'septic shock was performed...'

Response: We thank the reviewer for this comment. The manuscript has been grammatically reviewed and modified accordingly.

Reviewer \#2: The manuscript by Deniau and colleagues demonstrates the potential role of DPP3 in cardiac dysfunction in an experimental model of sepsis. The manuscript is important, however I have number of critiques/suggestions to improve the manuscript detailed below.

MAJOR

1\) What is the role of DPP3 in the heart? Is there any relationship between DPP3 and DPP4?

Response: We thank the reviewer for this interesting comment. Currently, exact roles of DPP3 in the heart and especially in cardiac cells are not completely understood. DPP3 is a ubiquitous cytosolic enzyme involved in oxidative stress metabolism. Extracellular, circulating DPP3 has a role in the cleavage of cardiovascular peptides (notably Ang II and IV) as well as in pain and inflammatory modulation. We previously demonstrated that cDPP3 is involved in myocardial depression when injected in healthy mice (Deniau et al. European Journal of Heart Failure 2020). Upon inflammation and cell death, it is observed that cDPP3 is increased in the bloodstream, which could lead to degradation of cardiovascular peptides and hemodynamic instability.

DPP4 is a serine protease localized in the membrane of cells while DPP3 is present in the cytosol. Like DPP3, it is a dipeptidyl aminopeptidase. Inhibition of DPP4 activity is of considerable interest for the therapy of type 2 diabetic patients. For now, there are no studies showing any relationship between DPP3 and DPP4. The number of DPP was conventionally added according to the time of its discovery (Prajapati et al. FEBS 2011).

The manuscript was modified according to this comment

Introduction section, page 1, line 24: "Exact roles of DPP3 in the heart and especially in cardiac cells are not completely understood."

2\) Why the antibody inhibits DPP3 activity? Is the epitope close to the active site of the enzyme?

Response: The humanized DPP3-inhibiting antibody Procizumab binds to a conserved, surface exposed loop in proximity to the active site. Crystal structures of human DPP3 in apo and substrate-bound forms show that the enzyme undergoes a large conformational change between the open (apo) state and the closed (substrate-bound state). Since the epitope targeted by Procizumab remains exposed in the surface in the open and closed states, it is expected that the antibody binds the enzyme regardless of its conformation and sterically blocks the transition between DPP3 catalytic states, therefore, inhibiting enzyme activity.

The manuscript was modified according to this comment.

Page 4, line 81: "Inhibition of DPP3 activity by PCZ

Generation, screening and development of humanized anti-DPP3 antibody PCZ was previously described \[7\]. In addition, the humanized DPP3-inhibiting antibody Procizumab binds to a conserved, surface exposed loop in proximity to the active site. Crystal structures of human DPP3 in apo and substrate-bound forms show that the enzyme undergoes a large conformational change between the open (apo) state and the closed (substrate-bound state). Since the epitope targeted by Procizumab remains exposed in the surface in the open and closed states, it is expected that the antibody binds the enzyme regardless of its conformation and sterically blocks the transition between DPP3 catalytic states, therefore, inhibiting enzyme activity."

3\) Why DPP3 activity was measured only in the plasma but not in the heart of the animals? Is DPP3 cleaved by a sheddase? Is this sheddase upregulated in sepsis?

Response: We thank the reviewer for this intriguing comment. Indeed, DPP3 activity was only measured in plasma since the antibody can only bind and inhibit DPP3 activity in plasma and not inside cells, e.g. cardiac cells. Although membrane-associated forms of DPP3 have been reported, we have not been able to detect membrane-bound DPP3 in a variety of tissues, such as heart, liver, kidney and lungs. To our understanding and based on a large body of literature, DPP3 is mainly an intracellular enzyme and, therefore, not exposed to the activity of sheddases. Nevertheless, we do agree that further studies are needed to specifically measure DPP3 activity and concentration in the heart of healthy and diseased animals.

The manuscript was modified in the limitation section according to this comment

Page 11, line 220: "Fourth, DPP3 activity was only measured in plasma since the antibody can only bind and inhibit DPP3 activity in plasma and not inside cells, e.g. cardiac cells.

4\) Very little is shown and discussed regarding the potential mechanisms by which DPP3 inhibition improves cardiac function in the setting of sepsis.

Response: Indeed, the potential mechanism of action by which DPP3 inhibition improves cardiac function is currently unknown in sepsis. This is a proof-of-concept study showing a role of DPP3 in myocardial dysfunction during sepsis. Cardiac and vascular haemodynamic measurements and further biological analyses should be performed in future preclinical studies to better understand the mechanism(s) of action of PCZ in the sepsis.

The manuscript was modified in the limitation section according to this comment.

Page 10, line 217: "Third, the mechanism of action of DPP3 and its inhibition by PCZ in septic cardiomyopathy is currently poorly understood."

5\) Was the lack of variation in heart rate among the three groups of rats expected?

Response: We thank the reviewer for this valuable comment. Indeed, the heart rate did not exceedingly vary during the first 120 min after PBS or PCZ injection. A decreasing trend in the PCZ group was, however, observed. We did observe an increase in stroke volume and cardiac output in this PCZ-treated group as specified in the manuscript (Page 8, line 164 : In contrast, heart rate (HR) and MBP measured at 120 minutes were similar in all CLP groups (Fig 2F and G)).

6\) MINOR

Please, replace angiotensin 2 by angiotensin II or Ang II.

Response: We thank the reviewer for this comment and we modified all the manuscript accordingly.

10.1371/journal.pone.0238039.r003

Decision Letter 1

Lionetti

Vincenzo

Academic Editor

© 2020 Vincenzo Lionetti

2020

Vincenzo Lionetti

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

10 Aug 2020

Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: a proof of concept study

PONE-D-20-10991R1

Dear Dr. Deniau,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Vincenzo Lionetti, M.D., PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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3\. Has the statistical analysis been performed appropriately and rigorously?
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4\. Have the authors made all data underlying the findings in their manuscript fully available?
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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